Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1615
This examiner grants 55% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19221438 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | Final Rejection | Veradermics, Incorporated |
| 18380350 | WATER-SOLUBLE SALT PARTICLE CONTAINING COMPOSITIONS AND POROUS MATERIALS MADE THEREFROM | Final Rejection | NORTHWESTERN UNIVERSITY |
| 17284947 | Softgels with solid or gel-like polymeric fill matrix | Non-Final OA | Bayer HealthCare LLC |
| 17582616 | MINI SOFTGEL NAPROXEN COMPOSITION | Non-Final OA | R.P. SCHERER TECHNOLOGIES, LLC |
| 18199614 | DRUG COMPOSITIONS AND METHODS OF PREPARING THE SAME | Final Rejection | Applied Materials, Inc. |
| 18683624 | PATCH AND PRODUCTION METHOD THEREOF | Non-Final OA | KANEKA CORPORATION |
| 17836661 | ORAL PRODUCT AND METHOD OF MANUFACTURE | Non-Final OA | NICOVENTURES TRADING LIMITED |
| 16707580 | ORAL PRODUCT AND METHOD OF MANUFACTURE | Non-Final OA | NICOVENTURES TRADING LIMITED |
| 19107055 | GADUSOL-CONTAINING SUNSCREEN FORMULATIONS | Non-Final OA | ARCAEA, LLC |
| 18054741 | PROCESS FOR PREPARING FILLED HARD-SHELL CAPSULES WITH (METH)ACRYLATE COPOLYMER BASED COATINGS WITH A CAPSULE-FILLING MACHINE | Non-Final OA | Evonik Operations GmbH |
| 17622315 | BLEND OF BEESWAX AND A LACTYLATE ESTER | Final Rejection | SYMRISE AG |
| 17566255 | WOUND SEALING POWDER | Non-Final OA | Biolife Delaware, L.L.C. |
| 18694042 | HIGH-DOSE COMPRESSIBLE DOSAGE FORMS MANUFACTURED BY SIMULTANEOUS MELT-COATING AND MELT-GRANULATION OF ACTIVE PHARMACEUTICAL INGREDIENTS | Non-Final OA | Janssen Research & Development, LLC |
| 18411193 | Pharmaceutical Composition and Method for Improving Biomechanical Integrity of the Pelvic Floor | Non-Final OA | Fempharma, LLC |
| 18343849 | ORAL TABLET WITH IMPROVED UNIFORMITY OF CONTENT OF ACTIVES | Final Rejection | FERTIN PHARMA A/S |
| 18684650 | COMPOSITION FOR PREVENTING AND TREATING CANCER THROUGH MITOCHONDRIAL METABOLISM REGULATION CONTAINING NANOGRAPHENE STRUCTURE | Non-Final OA | INBCT CO., LTD. |
| 18687403 | BONE GRAFT MATERIAL COMPRISING WHITLOCKITE | Non-Final OA | H&BIO CO., LTD. |
| 18681298 | LIPID-BASED COMPOSITION FOR ORAL ADMINISTRATION OF BRADYKININ B2-RECEPTOR ANTAGONISTS | Non-Final OA | PHARVARIS GMBH |
| 18681117 | COMPOSITION OF LIPID NANOPARTICLE CONTAINING VITIS VINIFERA EXTRACT, COSMETIC USES OF A COMPOSITION OF LIPID NANOPARTICLE CONTAINING VITIS VINIFERA EXTRACT, ANTIOXIDANT DERMOCOSMETIC PRODUCT AND FOR PREVENTING SKIN AGING AND SKIN CARE METHOD | Non-Final OA | ACHÉ LABORATÓRIOS FARMACÊUTICOS S.A. |
| 18423060 | HIGH MOLECULAR IODINE CONCENTRATION COMPOSITIONS, PHARMACEUTICAL FORMULATIONS, PREPARATION AND USES | Non-Final OA | I2PURE CORP. |
| 18418081 | INSTANT RELEASE PHARMACEUTICAL PREPARATION OF ANTICOAGULANT AND PREPARATION METHOD THEREFOR | Final Rejection | Jiangsu Vcare PharmaTech Co., Ltd. |
| 17920558 | NEW CAPSULE COMPOSITION FOR PERORAL ADMINISTRATION | Final Rejection | Vicore Pharma AB |
| 18533982 | PHARMACEUTICAL COMPOSITIONS AND PHARMACOKINETICS OF A GAMMA-HYDROXYBUTYRIC ACID DERIVATIVE | Non-Final OA | XWPHARMA LTD. |
| 18289326 | GASTRIC RESIDENCE SYSTEMS COMPRISING METHADONE | Non-Final OA | Lyndra Therapeutics, Inc. |
| 18487648 | SUSTAINED RELEASE OSMOTIC-CONTROLLED PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREOF | Non-Final OA | Anxo Pharmaceutical Co., Ltd. |
| 17796834 | AMORPHOUS SOLID DISPERSION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE | Non-Final OA | INSTITUT CURIE |
| 18469299 | COMPOSITIONS AND METHODS FOR IMPROVING GASTROINTESTINAL ABSORPTION OF ELECTROLYTES | Non-Final OA | IGH NATURALS, INC. |
| 18255244 | STABLE COATED SOLID PHARMACEUTICAL COMPOSITION OF AN OPIOID ANALGESIC AND AN ANTI-EPILEPTIC FOR PAIN | Final Rejection | LABORATORIOS SILANES S.A. DE C.V. |
| 18028625 | PHARMACEUTICAL COMBINATIONS OF STATINS AND FIBRATES FOR THE TREATMENT AND PREVENTION OF HYPERLIPIDEMIAS AND CARDIOVASCULAR DISEASE | Final Rejection | LABORATORIOS SILANES S.A. DE C.V. |
| 18198266 | Manufacturing Process for Metaxalone Tablets | Final Rejection | Primus Pharmaceuticals, inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy